The company
behind your programs

Programs run on people. Meet ours.

One strong legacy, redesigned as the next generation of biosimilar execution.

Polpharma Biologics is built for speed, flexibility, and smart execution.

From Zug, Switzerland, we take programs from concept to commercial supply.

In-house leadership directing a partner 
network as one system.

Purpose-built
for partners

what we do

Biologic medicines can change lives, but only if patients can reliably access them. Our purpose is to expand access to high-quality biologic therapies by building biosimilars designed for durability, affordability, and long-term supply.

our capabilities
1

Development & Manufacturing

2

Clinical development

3

Regulatory affairs

4

Quality

5

PM, ALM, LCM, IP

The people behind
the programs

Board of Directors & Investor

Hannes Teissl
Member of the Board of Directors
Philipp Leitner
Member of the Board of Directors
Joerg Windisch
Member of the Board of Directors
Gertjan Noordermeer
Member of the Board of Directors
Emmanuelle Lepine
Chairperson of the Board of Directors
Jerzy Starak
Investor

Enterprise

Stephanie Deitzer​
Lead Transformation & Communications
Cinthya Alber​
Office Manager & Administrative Support​
Ruth Blättler​
Head of People &Organisation​
Salima Fiandaca​
Head of Legal &Compliance
Akos Mile​
Head of Finance​
Olivia Darmuzey​
Responsible Person​
Veronica Gavrielides​
Senior Clinical QA Manager
Sarah Kotele
Device and combination product Quality Assurance Key Expert
Dominika Nowacka​
Specialist Documentationand QMS
Lucas Bachet​
Product Quality Assurance Principal and RP Deputy​
Salvatore Buglione​
Product Quality Assurance Principal
Katarzyna Walaszek​
Head of Quality​
Anjan Selz
Chief Executive Officer

Business

Magdalena Paczkowska​
Product Lead
Klaas Ehrig​
Head Alliance Management & LCM​
Łukasz Żemło
Director Business Development​
Theo Zografou​
Senior Director Business Development​
Paco Santamaria
Vice President Business Development​
Sameer Deshmukh​
Program Lead​
Kacper Szczygieł​
Program Lead​
Jaime Martinez Gago ​
Program Lead​
Gopal Rao
Chief Business Officer

Technology

Juan Carlos Gerena
Head of Supply Chain
Alessia Pacioni
Device Technology Key Expert​
Cornelia Hain
Device & Packaging Development Lead​
Alessandro Santini
DP & DS Principal​
Olaf Birkenmeier
Snr. Strategy Advisor​ TD & MNF
Pavel Motsinov
DP & DS Principle​
Patrick Schum
DP & DP Development Principal​
Thomas Göttler
DP & DP Development Principal​
Katarzyna Woldanska
Head of TD & MNF​
Sakshi Gupta
Regulatory Affairs Manager​
Alexandra Wille
Senior Regulatory CMC Manager​
Flavio Fossati
Senior Regulatory CMC Advisor​
Angela Villiger
Senior Expert Regulatory Affairs​
Vikas Jawalkar
Head of Regulatory Affairs​
Mateusz Borowiecki​
Clinical Trial Manager​
Sebastian Brzózy​
Clinical Trial Lead​
Monika Fus-Szewczyk​
Clinical Trial Lead​
Peggy Wu​
Clinical Trail Manager​
Serena Bongiovanni​
Clinical Trial Lead​
Laura Vannucci​
Associate Clinical Development Lead​
Sonja Höller​
Clinical Development Lead​
Karsten Roth​
Senior Director Clinical Research & Development​
Solomon Alva
Chief Technology Officer

Proven in practice. A track record built over decades of GMP and regulatory delivery.      

Our efficient operating model advances biosimilar programs and supports partners through approval and long-term supply.

1935
2019

Decades of GMP manufacturing, regulatory expertise, and global partnerships, built through Polpharma.

2013
2016

Entry into biologics, with dedicated R&D and development capabilities established to advance biosimilar programs

2019

First out-licensing agreements signed for biosimilar programs

2022

Regulatory filings submitted for lead biosimilars,Ranibizumab and Natalizumab

2023

First regulatory approvals and commercial launches of Ranibizumab and Natalizumab in key markets.

2024
Today

Global rollout of approved biosimilars, withthepipeline strengthened by additional molecules.

Our values

How we behave
when it matters most.

1

Velocity

Focus and urgency in practice. We make clear decisions and move programs forward with purpose.

2

Impact

We prioritize meaningful value, work that expands access and strengthens healthcare systems.

3

Belonging

We foster trusted relationships across teams and partners, strengthening outcomes through collaboration.

4

Empowerment

We place ownership in the hands of experienced people and support them to lead with accountability and confidence.

Let's build together.

If you want to explore what a partnership with us
could look like, we're ready to talk.